Authorized purpose: BriefCase is a radiological computer aided triage and notification software indicated for use in the analysis of non-enhanced CT and CTPA images. The device is intended to assist hospital networks and trained radiologists in workflow triage by flagging and communication of suspected positive findings of Intracranial Hemorrhage and Pulmonary Embolism pathologies. For the PE pathology, the software is only intended to be used on single-energy exams.
Clinical role
Triage and notification in parallel to standard-of-care reading: the worklist application pops up notifications of studies with suspected findings, prompting radiologists to assess the original images in PACS; cases stay in the standard reading queue.
Images and patients
CT/CTA · Brain; Chest/Lung
Key limitation
Keep in mind: Notifications include compressed preview images that are meant for informational purposes only and not intended for diagnostic use beyond notification. The device does not alter the original medical image and is not intended to be used as a diagnostic device.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: BriefCase is a radiological computer aided triage and notification software indicated for use in the analysis of non-enhanced CT and CTPA images. The device is intended to assist hospital networks and trained radiologists in workflow triage by flagging and communication of suspected positive findings of Intracranial Hemorrhage and Pulmonary Embolism pathologies. For the PE pathology, the software is only intended to be used on single-energy exams.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain; Chest/Lung Input: non-enhanced head CT and CTPA images; for the PE pathology, the software is only intended to be used on single-energy exams.
Who uses it?Intended users: Radiologist
What does the software produce?Output: Triage and flag suspected positive findings of Intracranial Hemorrhage and Pulmonary Embolism pathologies.
What is its most important limitation?Key limitation: Notifications include compressed preview images that are meant for informational purposes only and not intended for diagnostic use beyond notification. The device does not alter the original medical image and is not intended to be used as a diagnostic device.
Clinical takeaway. Clinical role: BriefCase is a radiological computer aided triage and notification software indicated for use in the analysis of non-enhanced CT and CTPA images. The device is intended to assist hospital networks and trained radiologists in workflow triage by flagging and communication of suspected positive findings of Intracranial Hemorrhage and Pulmonary Embolism pathologies. For the PE pathology, the software is only intended to be used on single-energy exams.
Evidence takeaway. Evidence from the reviewed source record: Study type: Stand-Alone Performance. Cases: 184. Sites: 3. Reported sensitivity: 90.6% (95% CI: 82.2%-95.9%). Reported specificity: 89.9% (95% CI: 82.2%-95.1%)
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
BriefCase is a radiological computer aided triage and notification software indicated for use in the analysis of non-enhanced CT and CTPA images. The device is intended to assist hospital networks and trained radiologists in workflow triage by flagging and communication of suspected positive findings of Intracranial Hemorrhage and Pulmonary Embolism pathologies. For the PE pathology, the software is only intended to be used on single-energy exams.
Triage and notification in parallel to standard-of-care reading: the worklist application pops up notifications of studies with suspected findings, prompting radiologists to assess the original images in PACS; cases stay in the standard reading queue.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The Worklist Application displays the pop-up text notifications of new studies with suspected findings when they come in." … "Presenting the radiologist with notification facilitates earlier triage by prompting the user to assess the relevant original images in the PACS.". Read from the exact FDA decision document on 2026-11-14.
Used in hospital networks to triage non-enhanced head CT and CTPA images for suspected intracranial hemorrhage and pulmonary embolism, with single-energy exams only for pulmonary embolism.
Exact FDA submission
Checked 2026-11-14
Packet wording: "BriefCase is a radiological computer aided triage and notification software indicated for use in the analysis of non-enhanced head CT and CTPA images." … "The device is intended to assist hospital networks and trained radiologists in workflow triage by flagging and communication of suspected positive findings of Intracranial Hemorrhage (ICH) and Pulmonary Embolism (PE) pathologies.". Read from the exact FDA decision document on 2026-11-14.
Notifications include compressed preview images that are meant for informational purposes only and not intended for diagnostic use beyond notification. The device does not alter the original medical image and is not intended to be used as a diagnostic device.
Exact FDA submission
Checked 2026-09-19
The exact indication states the preview-image, diagnostic-use, and unchanged-image boundaries.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
BriefCase-ICH and PE triage regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K190072
Samplen=184
Sites3
IndependenceIndependence not established
K190072
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K190072. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: non-enhanced head CT and CTPA images; for the PE pathology, the software is only intended to be used on single-energy exams.
Scope: Exact FDA submission. The exact indication states the two image types and the single-energy boundary for PE.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes DICOM images being received, saved, filtered and de-identified before processing, with notifications and compressed preview images sent to the Worklist desktop application on the radiology workstation desktop. Interface versions and local compatibility require confirmation.
Scope: Exact FDA submission. Packet wording: "DICOM images are received, saved, filtered and de-identified before processing." … "then notifications on flagged series are sent to the Worklist desktop application, thereby prompting preemptive triage and prioritization.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes three modules: an Aidoc Hospital Server, an Aidoc Cloud Server and a Worklist Application installed on the radiologist's desktop; DICOM exams are de-identified and uploaded to the cloud for analysis, and notifications return to the worklist application. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "The device consists of the following three modules: (1) Aidoc Hospital Server (AHS); (2) Aidoc Cloud Server (ACS); and (3) Aidoc Worklist Application that is installed on the radiologist’ desktop" … "The BriefCase time-to-notification includes the time to get the DICOM exam, de-identify it, upload it to the cloud, analyze and send a notification back to the worklist application.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Unresolved route: Triage and flag suspected positive findings of Intracranial Hemorrhage and Pulmonary Embolism pathologies.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes three modules: an Aidoc Hospital Server, an Aidoc Cloud Server and a Worklist Application installed on the radiologist's desktop; DICOM exams are de-identified and uploaded to the cloud for analysis, and notifications return to the worklist application. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The device consists of the following three modules: (1) Aidoc Hospital Server (AHS); (2) Aidoc Cloud Server (ACS); and (3) Aidoc Worklist Application that is installed on the radiologist’ desktop" … "The BriefCase time-to-notification includes the time to get the DICOM exam, de-identify it, upload it to the cloud, analyze and send a notification back to the worklist application.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The exact FDA package describes DICOM images being received, saved, filtered and de-identified before processing, with notifications and compressed preview images sent to the Worklist desktop application on the radiology workstation desktop. Interface versions and local compatibility require confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "DICOM images are received, saved, filtered and de-identified before processing." … "then notifications on flagged series are sent to the Worklist desktop application, thereby prompting preemptive triage and prioritization.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Aidoc's current public Security & Privacy page says its security work is led by a CISO and security team, that it has adopted the NIST Cybersecurity Framework, and that its platform runs on AWS and Azure using EDR, encryption, SIEM and CSPM tooling. The page's list of standards and certifications did not load as readable text, so no certification is stated here.
Vendor-wide
Checked 2026-10-25
Vendor-wide marketing statement, not an independent attestation. It does not establish certificate scope or expiry, the controls of this exact release, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.
The 510(k) summary states BriefCase is intended to assist hospital networks and trained radiologists in workflow triage by flagging and communication of suspected positive findings of intracranial hemorrhage and pulmonary embolism.
Exact FDA submission
Checked 2026-10-27
User qualification wording only; the summary specifies no training program or training offering for this device.
Aidoc's security page states that its platform runs on AWS and Azure and that customer data protection is achieved with the use of EDR, encryption, SIEM, CSPM and other technologies.
Vendor-wide
Checked 2026-10-27
Vendor statement, not an attestation. The page names Aidoc's platform generally and does not scope these capabilities to any specific product release; exact-release scope is not established. The page lists technology categories in use; it states no uptime, alerting or response-time SLAs.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
11Source classes checked
20Screened PubMed leads
6Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 20 PubMed and 6 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 20 PubMed and 6 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K190072 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Authorized purpose: BriefCase analyzes supported noncontrast head CT, head CTA, noncontrast cervical-spine CT, and CTPA examinations to triage suspected intracranial hemorrhage, large-vessel occlusion, cervical-spine fracture-related findings, and pulmonary embolism-related findings for trained professional review.
Modality
CT/CTA
Anatomy
Adult head, brain, cervical spine, pulmonary arteries, and thorax
Authorized purpose: Notification-only triage of adult non-contrast head CT for suspected intracranial hemorrhage and large-vessel occlusion, with parallel communication to trained clinicians during standard care.
Modality
CT/CTA
Anatomy
Brain and intracranial vessels: intracranial hemorrhage and LVO involving ICA, MCA-M1, and MCA-M2
Authorized purpose: Triage and notification of suspected intracranial hemorrhage or anterior-circulation LVO on acute non-contrast head CT; not primary diagnosis.
Modality
CT/CTA
Anatomy
Brain/head, including intracranial ICA and M1 for LVO and intracranial hemorrhage findings
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.